Clinical development of citalopram.
Willetts
J
J
Palanquin Corporation, Florida, New York, USA.
Lippa
A
A
Beer
B
B
D000293:Adolescent; D000328:Adult; D000368:Aged; D000818:Animals; D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D015283:Citalopram / Q000009:adverse effects / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003866:Depressive Disorder / Q000188:drug therapy* / Q000503:physiopathology; D004347:Drug Interactions; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012701:Serotonin / Q000502:physiology; D016896:Treatment Outcome
D018687:Antidepressive Agents, Second-Generation; D015283:Citalopram; D012701:Serotonin